Integrative metabolic profile of myelodysplastic syndrome based on UHPLC-MS.

Myelodysplastic syndrome (MDS) is neoplastic disease originating from hematopoietic stem cells, and hematopoietic stem cell transplantation (HSCT) is currently the most effective cure despite lenalidomide, azacytidine and decitabine were applied to relieve symptoms of MDS. The purpose of this study is to evaluate the changes of endogenous metabolites by UHPLC-MS (ultra performance liquid chromatography-mass spectrometry) metabolomics and to investigate related metabolic pathways related MDS. An untargeted metabolomics approach based on UHPLC-MS combined multivariate data analysis, including PLS-DA (partial least squares discrimination analysis) and OPLS-DA (orthogonal partial least squares discriminant analysis), was established to investigate potential biomarkers in plasma of MDS patients. As a result, 29 biomarkers were identified to distinguish MDS patients, HSCT patients and healthy controls, which were mainly related to inflammation regulation, amino acid metabolism, fatty acid metabolism and energy metabolism. It's worth mentioning that it is the first time that plasma metabolomics combined with hematopoietic stem cell transplantation was used to study of myelodysplastic syndrome alone. The identification of biomarkers and analysis of metabolic pathways could offer the possibility of discovering new therapeutic targets for MDS in the future.